Related Experiment Video

Updated: May 18, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

The role of CD14 gene promoter polymorphism in tuberculosis susceptibility

Ergin Ayaslioglu1, Fusun Kalpaklioglu, Ayse Baccioglu Kavut

  • 1Department of Infectious Diseases and Clinical Microbiology, Kırıkkale University School of Medicine, Kırıkkale, Turkey. eayasli@yahoo.com

Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
|October 6, 2012
PubMed
Abstract

Insights

The CD14-159C/T gene variant is not linked to tuberculosis development in a Turkish population. However, elevated soluble CD14 (sCD14) levels indicate increased immune cell activity in active tuberculosis patients.

Area of Science:

  • Immunology
  • Genetics
  • Infectious Diseases

Background:

  • CD14, primarily on monocytes/macrophages, is crucial for innate immunity against intracellular infections.
  • CD14 gene promoter polymorphisms have been linked to various infectious diseases.
  • The CD14-159C/T polymorphism is a specific genetic variation under investigation.

Purpose of the Study:

  • To examine the association between the CD14-159C/T polymorphism and tuberculosis risk.
  • To assess serum soluble CD14 (sCD14) levels in relation to tuberculosis.
  • To investigate these factors within a Turkish population.

Main Methods:

  • Prospective study involving 88 tuberculosis patients and 116 controls.
  • Genotyping of the CD14-159C/T polymorphism using polymerase chain reaction - restriction fragment length polymorphism.
  • Quantification of serum sCD14 levels via enzyme immunoassay.

Main Results:

  • No significant difference in CD14-159C/T genotype distribution between tuberculosis patients and controls.
  • Serum sCD14 levels were significantly higher in active tuberculosis patients compared to inactive cases and healthy controls.
  • No association was found between sCD14 levels and CD14-159 genotypes.

Conclusions:

  • The CD14-159C/T polymorphism does not appear to influence tuberculosis development in this Turkish cohort.
  • Elevated serum sCD14 levels in active tuberculosis highlight the role of mononuclear phagocyte system activation.
  • Further research may be needed to explore other genetic or environmental factors in tuberculosis pathogenesis.

More Related Videos

Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF107:42

Fluorescence Assays for the Study of Mycobacterium tuberculosis Interaction with the Immune Receptor SLAMF1

Published on: February 28, 2025

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories: